Stay updated on Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the usual study record content and navigation. This indicates access to the record is blocked, preventing viewing of the study details.SummaryDifference18%

- Check14 days agoNo Change Detected
- Check28 days agoChange DetectedThe study record now lists NIH grant/contract years 2018 and 2023 in the funding information, and the revision label was updated from v3.6.5 to v3.6.6.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page now displays an error screen instead of the study record. This prevents access to the study details and related information on NCT03815058.SummaryDifference17%

- Check64 days agoChange DetectedThe page revision was updated to v3.6.4, indicating a backend update to the ClinicalTrials.gov page. This update appears to be a software version change rather than a modification to study details.SummaryDifference0.0%

- Check86 days agoChange DetectedA new revision tag v3.6.3 was added and the previous v3.6.2 tag was removed from the page, updating the revision history.SummaryDifference0.0%

- Check93 days agoChange DetectedThe page's revision label updated from v3.6.0 to v3.6.2, indicating a minor behind-the-scenes update to the page version.SummaryDifference0.0%

Stay in the know with updates to Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page.